Background Intestinal metaplasia (IM) is a gastric cancer precursor lesion (GCPL) and an extremely high risk factor for progression to gastric cancer (GC). Clinical guidelines recommend that patients with extensive IM undergo a gastroscopy every 3 years. However, protein biomarkers that indicate a transition from IM to GC are lacking. Our group recently identified an interferon-alpha (IFNa)-responsive gene, Schlafen 4 (Slfn4), in immune cells that correlates with metaplastic changes in Helicobacter-infected mice. We therefore tested the hypothesis that a human homolog of Slfn4, namely, Schlafen 5 (SLFN5), correlates with progression of GCPL to GC. Methods Jurkat T-lymphoid and HL-60 myeloid cell lines were treated with IFNa, and SLFN5 mRNA was quantified by quantitative PCR. SLFN5 protein expression in the inflamed gastric mucosa was co-localized to specific immune cell types by immunohistochemistry using CD20, CD2, and MAC2 antibodies. SLFN5 expression was also determined by immunohistochemistry in formalin-fixed paraffin-embedded samples from individuals with non-atrophic gastritis, atrophic gastritis, complete IM, incomplete IM, and GC, respectively. Results The IFNa treatment of Jurkat and HL-60 cells induced SLFN5 mRNA. SLFN5 protein was expressed mainly by T lymphocytes in inflamed gastric mucosa. The highest level of SLFN5 expression was observed in patients with IM that progressed to GC. Receiver operating characteristic curves demonstrated that correlating SLFN5 expression with the histologic diagnosis of IM significantly increased the probability of identifying patients who may progress to GC. Conclusion In this study population, elevated SLFN5 protein expression in patients with IM correlated with progression to GC.
Introduction
Gastric cancer (GC) is preceded by a series of events that include chronic atrophic gastritis, intestinal metaplasia (IM), and dysplasia [1] . IM is subclassified as complete (small intestinal type) or incomplete (colonic type), in which the latter is considered to be the most advanced stage of IM [2] . The initiating event leading to gastric carcinogenesis is atrophic gastritis typically due to infection with Helicobacter pylori and subsequent infiltration of cytokinesecreting cells into the lamina propria [3] .
GLI1 is a transcription factor and a downstream target of the Hedgehog (Hh) signaling pathway. We recently showed that Helicobacter-infected Gli1 -/-mice do not develop gastric atrophy and spasmolytic polypeptide-expressing metaplasia, a pre-neoplastic lesion, compared to wild-type (WT)-infected mice, demonstrating that Hh signaling is required for progression from inflammation to mucosal transformation [4] . Microarray analysis comparing stomach tissue from Helicobacter-infected wild type versus Gli1 -/-mice revealed that a myeloid differentiation factor and Gli1 target gene, called Schlafen 4 (Slfn4), was upregulated in the gastric mucosa of WT mice that develop the metaplasia [4] .
The Schlafen (SLFN) family consists of highly conserved type 1 interferon-regulated proteins that control T-cell development and maturation. When overexpressed, they impair T-cell proliferation and activation [5] . There are ten murine and five human isoforms divided into three groups based upon their secondary structure. Although Slfn4 in mice correlates with atrophy and metaplasia, this isoform does not exist in the human genome. The predominant type 1 interferon-regulated SCHLAFEN gene in the human genome is SLFN5 [6] .
Considering the increased level of pro-inflammatory cytokines in chronic atrophic gastritis [7] and several studies showing that IM increases the risk of GC relative to other gastric lesions [2, 8] , we hypothesized that SLFN5 might be an interferon-alpha (IFNa)-regulated gene in human immune cells that correlates with a higher likelihood of gastric tumorigenesis. To test this hypothesis, we used samples from a follow-up study to examine whether SLFN5 protein expression in human gastric samples of IM correlates with histologic progression to GC.
Materials and methods

IFNa induction of SLFN5 in human cell lines
Jurkat cells are a human T lymphoblastoid cell line derived from an acute T-cell leukemia (ATCCÒ TIB-152; American Type Culture Collection, Manassas, VA). HL-60 cells are human promyelocytic leukemia cell line (ATCCÒ CCL-240; American Type Culture Collection). HL-60 cells were cultured at 37°C with 5 % CO 2 in Iscove's Modified Dulbecco's Medium (IMDM; Life Technologies, Carlsbad, CA) plus 20 % fetal bovine serum (FBS). Jurkat cells were cultured in RPMI 1640 media supplemented with 10 % FBS, 100 U/ml penicillin, 100 lg/ml streptomycin in 5 % CO 2 at 37°C. Both cell lines were treated with human recombinant INFa (IFN2a, 1000 IU/ml, #11105-1; Interferon Source, Piscataway, NY). After removing the media, total cell RNA (500 ng) was prepared in TRIzolÒ reagent (Life Technologies) for quantitative PCR (reverse transcriptase-qPCR) in a Bio-Rad C1000 Thermocycler TM with the CFX96 TM real time attachment and CFX Manager software v.1.5 (Bio-Rad Laboratories, Hercules, CA). TaqManÒ probes and the TaqMan Gene Expression Assay (Life Technologies) were purchased for SLFN5 (Hs00288058_m1) and 18S RNA (Hs 99999901_s1) and normalized to beta actin (#Hs01060665_g1). Normalized values for IFNa-treated samples (N = 9) were compared to untreated controls (N = 9) using Boots ratio statistical software [9] .
To validate the specificity of the induction, Jurkat cells were transfected with hSLFN5 siRNA (SC94178; Santa Cruz Biotechnology, Dallas, TX) or a control siRNA using Lipofectamine (RNAiMAX reagent kit; Life Technology) according to the manufacturer's instructions. Two days after transfection, cells were treated with IFNa (800U/ml) for 24 h and then collected on slides by centrifugation for staining [3, 3 0 -diaminobenzidine (DAB)] with SLFN5 antibody.
Patient samples
Expression of SLFN5 protein was determined by immunohistochemistry on three sources of human tissue: a commercial tissue microarray of human gastric mucosa, archived clinical samples from the Soria follow-up study [8] , and clinical samples from Marañon Hospital (Madrid, Spain). The four commercial tissue microarrays (#ST1001, #ST805, #ST806, #ST00011b; US Biomax Inc., Rockville MD; http://www.biomax.us/tissue-arrays) contain normal gastric mucosa (N = 15), superficial and chronic gastritis (N = 76), atrophy (N = 57), dysplasia (N = 11), and GC (N = 106).
Clinical samples were formalin-fixed paraffin-embedded (FFPE) blocks from precancerous lesions at recruitment from a follow-up study with GC as the end-point, carried out in the Province of Soria (Spain), whose inhabitants have one of the highest risks for GC in Spain [8] . Briefly, patients who underwent endoscopy and gastric biopsy from 1988 to 1994 with the diagnosis of non-atrophic gastritis (NAG, N = 26), multifocal atrophic gastritis (MAG, N = 49), and complete (CIM, N = 44) or incomplete IM (IIM, N = 54) were invited to undergo a follow-up biopsy between 2005 and 2007. This study design enabled histologic changes in the gastric mucosa after an average follow-up interval of 12.5-years following the first endoscopy to be documented. Since none of the original IM samples analyzed were from lesions that progressed to GC, we included additional samples of CIM (n = 6) and IIM (n = 19) from patients who had undergone an endoscopy and/or biopsy at the same hospital and who after a similar mean follow-up of 12 years had progressed to GC. Normal gastric mucosa (n = 41) and GC (n = 67) tissue samples from the same hospital were also analyzed by immunohistochemistry to assess the level of SLFN5 protein expression.
A total of 281 clinical samples were analyzed, and the demographics are presented in Table 1 . H. pylori infection was determined by Giemsa staining, urea breath tests, or documentation of a previous infection. An independent series of archived gastric specimens from the Gregorio Marañón Hospital (Madrid) consisting of tissues showing CIM ? GC (n = 21) and CIM ? No GC (n = 29) was included to enable independent validation of the results from the Soria study. The samples in this series were obtained from 1518 patients diagnosed with IM at Marañon Hospital, based on 4310 pathology reports from 1990 to 2008. Of these 1518 patients with IM, 181 developed GC; however, paraffin blocks were recovered for only 21 of these. The 29 samples forming the control group were selected from the 1518 patients who did not develop GC and who were age-matched to the cases; these samples were collected at approximately the same time as those from patients with GC. The Helicobacter status is not known for the Marañon cases. All patients from the Soria study signed an informed consent giving permission for the procedures performed in the study. No informed consent was required for the use of the Marañón FFPE samples because all of archived tissue used in this study was acquired before the Spanish Biomedical Research law (14/ 2007) . The protocols were approved by the Ethical Committees of Hospital General Virgen del Mirón Hospital in Soria, the University Hospital of Bellvitge-Catalan Institute of Oncology, and the Gregorio Marañón Hospital.
SLFN5 detection by immunohistochemistry
The FFPE samples from clinical studies were stained using the rabbit-specific streptavidin-biotin immune-enzymatic antigen detection system (ab64261; Abcam plc, Cambridge, UK). Sections (thickness 4 lm) were prepared and incubated overnight at 60°C prior to deparaffinization in xylene-alcohol series, followed by rehydration in 19 phosphate buffered saline (PBS). Antigen retrieval was performed by boiling the slides in 10 mM sodium citrate buffer, pH 6, for 45 min. After cooling to room temperature, the slides were washed twice in 19 TBS-T [Tris buffered saline (TBS), 0.1 % Triton X-100], immersed for 10 min in H 2 O 2 to deplete endogenous peroxidase, and then rinsed three times in TBS-T. Nonspecific binding sites were blocked with Protein Block (ThermoFisher Scientific, Waltham, MA) for 10 min. The slides were then incubated for 90 min with rabbit anti-human SLFN5 (ab121537; Abcam) antibody at a 1:500 dilution in 19 TBS-T, followed by two rinses. Following incubation with the biotinylated goat secondary antibody for 10 min, the slides were rinsed and then incubated for 10 min with streptavidin peroxidase, followed by two additional rinses. The reaction product was visualized with DAB substrate for 10 min and counterstained with Gill's hematoxylin. The secondary antibody without SLFN5 primary antibody was used as a negative control, and the positive control was human nasopharynx as recommended by the manufacturer (Abcam).
An independent series of samples from Marañon Hospital was processed on a Dako immunohistochemistry (IHC) instrument (Aligent Technologies, Santa Clara, CA) using the same protocol as described above, with a minor modification. The SLFN5 staining pattern was confirmed using ten additional human gastric samples with SLFN5 antibody (HPA 017760; Sigma-Aldrich, St. Louis, MO) [6] . Replicate IHC scoring was blindly performed by OC and by a pathologist (MLP).
Immunohistochemical scoring of SLFN5
Expression of SLFN5 on the tissue arrays and clinical samples was scored by one of the authors (OC) blinded to the diagnoses using an Olympus BX60 microscope (Olympus Corp., Tokyo, Japan) at 2009 magnification. SLFN5 nuclear staining was quantified independently for stroma and gastric glands using the H score, which is a semi-quantitative method of evaluating positively stained cells: [(% of low intensity-stained cells 9 1) ? (% medium intensity-stained cells 9 2) ? (% of high-intensitystained cells 9 3)] [10] . Intra-epithelial lymphocytes were included in the stromal score. Depending on the size of the tissue section, between five and 20 fields were examined. The H score for each stained slide was calculated as the mean of all fields analyzed. When more than one slide per subject was stained, the final H score was the mean of the scores from the different slides analyzed. The mean H score for each subject was plotted against the histologic diagnosis (i.e., normal, NAG, MAG, IM subtypes and GC).
Co-localization of SLFN5, CD2, CD20 and Mac2
To determine which cell type expressed SLFN5 in the gastric mucosa, cell surface markers CD20 (B-cells), CD2 (T-cells), or Mac2 (myeloid cells) were co-localized with SLFN5 using an intestinal metaplastic tissue section that progressed to GC. Antigen retrieval was made in sodium citrate (10 mM, pH 6) for 15 min, followed by washing with 19 TBS and then blocking with 20 % goat serum. The primary CD20 Ab (ab9475; Abcam) was diluted 1:50, then applied to the tissue at 4°C and incubated overnight. After washing with 19 TBS, a 1:200 dilution of biotinylated goat anti-mouse secondary antibody (BA-9200; Vector Laboratories, Burlingame, CA) was applied for 30 min and then washed with 19 TBS. Tissue slides were incubated with ABC-AP reagent (Vectastain ABC-AP kit; Vector Laboratories) for 30 min and then washed with 19 TBS. The reaction product was visualized by incubating with alkaline phosphatase for approximately 20 min (SK-5100; Red AP Substrate kit; Vector Laboratories) after dilution in 100 mM Tris-HCl, pH 8.5, followed by rinsing in water with 19 TBS. After this step, the same protocol for SLFN5 staining was performed after the H 2 O 2 block for SLFN5. 19 TBS was used for all final rinses before air-drying. To co-localize with the T-cell marker, CD2 (ab131276; Abcam) antibody was incubated at a 1:100 dilution in 19 TBS with 1 % bovine serum albumin (BSA) overnight at 4°C. The sections were incubated with biotinylated goat anti-rabbit secondary antibody for 10 min and then rinsed in 19 TBS. To detect myeloid/macrophage lineages, we incubated the Mac2 antibody (Cat. #14-5301; eBioscience, San Diego, CA) at a 1:200 dilution in 19 TBS with 1 % BSA for 1 h at room temperature. The sections were incubated with a 1:200 dilution of biotinylated goat anti-rat secondary (BA-9400; Vector Laboratories) for 30 min. The slides were then incubated with the Vectastain ABC-AP reagent for 30 min and incubated in the dark for 30 min using the BCIP/NBT substrate (SK-5400; Vector Laboratories) diluted in 100 mM Tris-HCl with 0.1 % Tween, pH 9. The stained slides were rinsed in water and dehydrated but were not counterstained with hematoxylin prior to being covered with a coverslip.
Statistical analysis
Baseline quantitative variables were expressed as the mean ± standard deviation or as the median with the 25th and 75th percentiles (interquartile range), depending on whether the variable followed a normal distribution or not, using the D'Agostino and Pearson omnibus normality test. Qualitative variables were expressed as frequencies and percentages. The Kruskal-Wallis test was performed to assess differences in the SLFN5 stromal score among the Soria samples at recruitment (Normal, NAG, MAG, CIM, IIM, and GC). The Mann-Whitney test was used to compare SLFN5 stromal scores of each IM subtype that progressed to GC versus those that did not progress to GC (CIM ? GC vs. CIM ? Not GC; IIM ? GC vs. IIM ? Not GC). We clustered the H scores into four categories: 0 B H score \ 10 (negative); 10 B H score B 100 (weakly positive); 100 B H score B 200 (moderately positive); 200 \ H score B 200 (strongly positive) [11] .
To assess the role of SLFN5 stromal expression as a prognostic indicator of IM progression to GC, we constructed two logistic regression models with or without the categorized SLFN5 stromal H score, adjusting by sex, age, and type of IM (CIM, IIM) as potential confounding variables that could influence GC progression. H. pylori infection was not included as a confounding factor because the bacterium is not present in the advanced stages of gastric carcinogenesis. In order to increase statistical power, the odds ratios (OR) and confidence intervals (95 % CI) for the categorical stromal H scores were calculated using the positive versus the negative H score, with the negative score used as the reference group. We constructed receiver operating characteristic (ROC) curves for both logistic regression models (with and without SLFN5 protein expression data) and calculated the area under the curve (AUC). To determine whether adding the SLFN5 stromal H score significantly improved the likelihood of IM progression to GC, we applied the likelihood-ratio test (LRT). All analyses were performed on the IIM and IM samples and not the CIM samples separately due to the low number of CIM cases progressing to GC (n = 6; Table 1) in the Soria follow-up study. SAS version 9.0 software (SAS Institute, Cary, NC) was used for the statistical analysis. Significance was set at p \ 0.05.
Results
Type I interferons induce expression of both the murine Slfn4 gene in myeloid cells [12] and the human SLFN5 gene in malignant melanoma [6] . Therefore, we examined whether IFNa induces SLFN5 expression in human immune cells and whether if plays a similar role as Slfn4 in the inflamed stomachs of Helicobacter-infected mice. A dose-response curve and time-course for IFNa in the HL-60 monocyte and Jurkat T-lymphocyte lines revealed a rapid and significant (p \ 0.05) induction of SLFN5 mRNA within 4-8 h (Fig. 1a-c) . SLFN5 protein was specifically detected in Jurkat cells by IHC since siRNA knockdown of the protein abolished staining (Fig. 2a, b) . The same antibody was used to stain human tissue sections. When we co-stained for SLFN5 in clinical samples from a patient with IIM ? GC (also see Fig. 4f for area with IIM) using immune surface markers, most of the SLFN5-positive cells in the lymphoid follicle were T cells and not B cells since there was co-localization with CD2 (Fig. 3c,  d ) but not CD20 (Fig. 3a, b) . SLFN5-expressing macrophage cells were scattered through the gastric lamina propria and co-localized with the Mac2 macrophage protein marker (Fig. 3e, f) .
Since IFNa was able to induce SLFN5 expression in human immune cells, we examined SLFN5 protein expression in human gastric tissue by IHC. First, we examined SLFN5 expression in commercial tissue microarrays of human gastric tissue, which revealed higher SLFN5 protein levels in the samples with atrophy and frank carcinoma (data not shown). Although samples with chronic atrophic gastritis exhibited an increase in SLFN5 expression, the increase was not statistically significant compared to that in samples from healthy subjects. Since the commercial array did not provide sufficient clinical details and follow-up information, archived tissue from a follow-up study of GC precursor lesions (GCPLs) from Soria, Spain were analyzed for SLFN5 expression by IHC [8] .
In these samples, SLFN5 protein expression, based on IHC, was either completely negative of weakly positive in the normal gastric mucosa (Fig. 4a) . The intensity of SLFN5 staining was generally higher in the gastric stroma than in the gastric glands (Fig. 4b) , as expected based upon known Schlafen gene expression in murine and human hematopoietic cells [4, 13] . SLFN5 expression was observed in samples from patients with atrophic gastritis, IM, and both intestinal and diffuse subtypes of GC (Fig. 4c-j) . More intense staining in areas of organized inflammatory collections, which typically are composed primarily of lymphocytes and myeloid cells, was observed in IM-GCs.
The widely accepted H score, which is commonly used for the semi-quantitation of estrogen receptors in breast cancer by IHC [10] , was used to quantify the changes in gastric SLFN5 expression in the archived specimens from the Soria follow-up study. SLFN5 expression increased with lesion severity until GC developed, at which stage expression was reduced (Table 1; Fig. 5 ). Significant differences between the stromal H scores for the major histological groups (Normal, NAG, MAG, CIM, IIM, and GC; p = 0.0033) were observed. In addition, stromal expression of SLFN5 was greatest in IM that progressed to GC (IM ? GC) when compared to IM that did not progress (IM ? Not GC; p \ 0.0001; Table 1 ; Fig. 5 ). Similar results were obtained when incomplete IM that progressed to GC (IIM ? GC) was compared to that which did not progress (IIM ? Not GC, p \ 0.0001; Table 1 ). This analysis was not performed in CIM due to the low sample size of CIM ? GC (n = 6).
Logistic regression analysis showed that the SLFN5 stromal score was a significant risk factor for IM (CIM ? IIM) progression to GC (OR 18.1, 95 % CI 4.14-79.1, p = 0.0001), as well as for IIM progression (OR 71.3, CI 95 % 7.14-712.9, p = 0.0003). The ROC curve obtained when SLFN5 expression was included in the logistic regression model for the IM (CIM ? IIM) samples indicated an AUC of 0.912, which was 12.9 % greater than the AUC obtained when the SLFN5 expression was not included in the model (AUC = 0.783). The difference between these two curves was significant (p \ 0.0001) after applying the LRT test (Fig. 6a) . When only IIM samples were considered, the AUC was 0.953 when the SLFN5 H score was included in the model compared to an AUC of 0.756 when the H score was not included. This 19.7 % increase in the AUC was again significant (p \ 0.0001) after applying the LRT test (Fig. 6b) . Therefore, in the context of IM of both subtypes, the SLFN5 H score increases the discrimination effect to 91 %, and when the IIM subtype is specifically considered, discrimination was higher at 95 %. A similar analysis for CIM independent of IIM could not be made with the Soria specimens due to the low sample size. Therefore, samples from a third hospital (Marañón, Madrid) were collected and processed. Analysis of SLFN5 protein expression in the Marañón samples independently by two of the authors (OC and MLP) did not reach statistical significance. However, both authors found a trend towards a higher risk of progression in SLFN5-positive samples of CIM when compared to the cases that did not progress to cancer (OR 1.93, 95 % CI 95 % 0.57-6.58 and OR 2.95, 95 % CI 0.80-10.90, respectively).
Discussion
Based upon our prior characterization of murine Slf4 overexpression in Helicobacter-induced metaplasia [4] , we examined whether a human SCHLAFEN gene homolog correlated with pre-neoplastic changes in the stomach. We report here that SLFN5 protein expression can indeed improve the identification of patients at greater risk for GC once they have developed IM. GC is a slow, progressive process that emerges from metaplastic changes occurring as a result of subsequent sustained inflammation initiated Fig. 3 Co-localization of SLFN5 with hematopoietic markers in human gastric mucosa of subjects with intestinal metaplasia (IM). SLFN5 protein expression was detected using horseradish peroxidase with the diaminobenzidine substrate and co-labeled with antibodies to detect B cells (CD20), T cells (CD2), or macrophages (Mac2) using the alkaline phosphatase secondary and red or blue substrates. The colocalization was performed on a lymphoid aggregate in the gastric tissue sample shown in Fig. 4f by H. pylori infection. With the exception of histology demonstrating IM on endoscopic biopsies, there are no clinical biomarkers for this deadly disease. Therefore, we evaluated samples from a long-term follow-up study of GCPLs with histological diagnoses made at the time of recruitment and at the end of a 12.5-year follow-up period. Guidelines for the management of GCPL include endoscopic surveillance every 3 years for extensive IM [14] ; however, there are no biomarkers to predict which patients with IM are most likely to develop GC over time. Taking into account that the incidence rate for GC is 3.77 cases for every 1000 IM patients after 5 years based on the results of the Soria study [8] , it is possible that highly expressed proteins may identify which IM patients are predisposed to eventually develop cancer.
We first demonstrated that IFNa, which is increased in patients infected by H. pylori [7] , induces the in vitro expression of SLFN5 in human T and monocyte cell lines. We then confirmed that SLFN5 is expressed in human gastric T and macrophage cells of the inflamed stomach in vivo. This led to our study of SLFN5 expression in the gastric mucosa of human subjects and our finding that SLFN5 expression was higher in IM and IIM that progressed to GC (IM ? GC and IIM ? GC) than in the same lesions that do not progress to GC (IM ? Not GC and IIM ? Not GC). Therefore, the addition of a score for SLFN5 protein expression in immune cells to the classification of histological subtype IM or even total IM may increase the probability of identifying patients that would eventually develop GC, based on AUCs. This conclusion was reached by comparing ROC curves with and without the SLFN5 stromal H score. When we analyzed SLFN5 staining in independent samples from another population (Marañón Hospital), the differences were suggestive but did not reach statistical significance, which we speculate is due to the relatively small sample size. However, only CIM samples were identified in those cases, which might reflect the fact that the prevalence of GC in Madrid is lower than in Soria [15] . Using the Madrid samples, the IHC scoring employed in our study showed a similar trend of higher SLFN5 expression in patients that progressed to GC compared to those that did not progress.
Few studies have examined whether protein biomarkers are present in patients with GCPLs who eventually progress to GC. In a study of 93 patients with gastric atrophy and metaplasia, 34 patients who ultimately developed GC 2 years later had significantly higher levels of both inducible nitric oxide synthase and nitrotyrosine [16] . An IHC study of 396 patients with GCPLs showed elevated MG7-Ag and COX-2 expression in patients with IM who progressed to dysplasia compared to non-IM controls. Samples which showed positive staining for both markers were associated with a significantly higher risk for progression to GC (OR 22.7, p \ 0.005) than those which showed no positive staining [17] .
Our earlier observations in a mouse model of Helicobacter infection showed that Slfn4 was expressed in a myeloid population that also expressed interleukin 1-beta and TNFa proinflammatory cytokines [4] . Surface marker analysis of these cytokine-producing cells indicated that they were CD11b
? and Gr-1 ? , which is suggestive of myeloid-derived suppressor cells, a population of immature myeloid cells that inhibit the proliferation of cytotoxic T cells. Suppression of cytotoxic T cells by SLFN5-producing cells could create a permissive environment for tumor cell growth once IM develops [18] . In the mouse model, Slfn4 expression was Gli1-dependent, indicating that the Hedgehog signaling pathway regulates the quality of the gastric immune response [4] .
Previous research of Schlafen genes (including SLFN5) indicates that these genes are upregulated in mature CD4
? and CD8
? thymocytes and in peripheral resting T cells and that they are downregulated after T-cell stimulation [13, 19] . In the SLFN8 (group III) transgenic mouse, elevated T-cell expression was found to partially blocked thymocyte transition to mature T cells, and transgenic T cells exhibited a significant reduction in the proliferative response [19] . Furthermore, transgenic expression of SLFN1 in thymocytes and fibroblasts causes cell cycle arrest [20] . SLFN5 expression is downregulated in peripheral T cells stimulated by T-cell receptors, suggesting that it negatively regulates T-cell growth [20] . In addition, the results of a recent study show that IFNa signaling induces Schlafen genes, precluding T-cell activation, and the high basal expression of SLFN5 in resting T cells, suggest that this gene plays an active role in maintaining T-cell quiescence [13] . Based on our results and those reported in the previous literature, we speculate that IFNa induction of SLFN5 in T cells and possibly macrophages might maintain T cells in a non-activated or quiescent state dampening their response to environmental cues. Suppression of CD8 ? -cytotoxic T-cell activation can create a permissive environment for neoplastic transformation [18] . A recent study suggested that the SLFN 5-like gene SLFN12L is associated with T-cell suppression, a function consistent with myeloid-derived suppressor cell function that creates an immune environment permissive for cancer development [13] . Results from additional studies suggest that those T cells which do not attack the tumor might express programmed death-ligand 1 (PD-L1) or its receptor and would be amenable to anti-PD therapies [21] . We can only speculate at this point which additional markers these SLFN5
? cells express and suggest that future studies with freshly isolated tissue is necessary to further characterize the function of these cells. Immunohistochemical analysis of SLFN5 protein on endoscopic biopsies might provide clues to the likelihood of progression to GC. However, implementation of such analyses into clinical practice will require a prospective study of SLFN5 expression in patients at risk for developing GC. 6 Receiver operator characteristic curves for logistic regression models of IM (a) and IIM (b) with or without the SLFN5 stromal score. Logistic regression models were constructed with histological diagnosis, sex, age and with or without categorized SLFN5 stromal score H, as variables. The p value of the loglikelihood ratio test comparing the score with versus without the stromal score is indicated for each model. Broken line (blue) model with SLFN5 stromal score, solid line (red) model without the SLFN5 stromal score. Area under the curve values are also shown as percentages
